bioMérieux S.A. (FRA:EYWN)

Market Cap	14.01B
Revenue (ttm)	3.98B
Net Income (ttm)	432.20M
Shares Out	n/a
EPS (ttm)	3.64
PE Ratio	32.42
Forward PE	26.09
Dividend	0.90 (0.73%)
Ex-Dividend Date	Jun 9, 2025

Volume	n/a
Average Volume	55
Open	122.90
Previous Close	119.80
Day's Range	122.90 - 122.90
52-Week Range	88.90 - 122.90
Beta	n/a
RSI	50.98
Earnings Date	Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.